Breast Cancer Research and Treatment

, Volume 51, Issue 2, pp 183–188

Adrenal androgens and human breast cancer: A new appraisal

  • John B. Adams
Article

Abstract

A clearer picture of the role of adrenal androgens in the etiology of breast cancer is beginning to emerge. Women who develop breast cancer in premenopausal years tend to have subnormal serum levels of adrenal androgens, while subjects who develop the disease in postmenopausal years have supranormal levels of these hormones. Androgens, by acting via the androgen receptor, oppose estrogen-stimulated cell growth in premenopausal years. In postmenopausal women, elevated adrenal androgen levels stimulate cell growth by the action of the unique adrenal androgen 5-androstene-3β,17β-diol, also termed hermaphrodiol, via its combination with the estrogen receptor in a hormone milieu lacking, or having low concentrations of, the classical estrogen 17β-estradiol.

adrenal androgens breast cancer 5-androstene-3β,17β-diol hermaphrodiol estrogen receptor 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beaulieu EE, Corpechot C, Dray F, Emilozzi R, Lebean M, Mauvais-Jarvis P, Robel P: An adrenal-secreted ‘androgen’: dehydroepiandrosterone sulfate, its metabolism and a tentative generalisation on the metabolism of other steroid conjugates in man. Recent Prog Hormone Res 21: 411–500, 1965Google Scholar
  2. 2.
    Allen BJ, Hayward JL, Merivale WMH: The exeretion of 17-kestosteroids in the urine of patients with carcinoma of the breast. Lancet 1: 496–497, 1957Google Scholar
  3. 3.
    Zumoff B: Hormone profiles and the epidemiology of breast cancer. In: Stoll BA (ed) Endocrine Relationships in Breast Cancer. Heinman, London, 1982, pp 3–47Google Scholar
  4. 4.
    Adams JB: Control of secretion and the function of C125-steroids of the human adrenal gland. Mol Cell Endierinol 41: 1–17, 1985Google Scholar
  5. 5.
    Bulbrook RD, Hayward JL, Wang DY, Thomas BS, Clark GMG, Allen DS, Moore JW: Identification of women at high risk of breast cancer. Breast Cancer Res Treat 7(Suppl): 5–10, 1986Google Scholar
  6. 6.
    Bulbrook RD, Thomas BS: Hormones are ambiguous factors for breast cancer. Acta Oncologica 28: 841–847, 1989Google Scholar
  7. 7.
    Zumoff B, Levin J, Rosenfeld RS, Markham M, Strain GW, Fukushima DK: Abnormal 24-hr mean plasma concentration of dehydroepiandrosterone and dehydroepiandrosterone sulfate in women with primary operable breast cancer. Cancer Res 41: 3360–3363, 1981Google Scholar
  8. 8.
    Gordon GB, Bush TL, Helzlsouer KJ, Miller SR, Comstock GW: Relationship of serum levels of dehydroepiandrosterone and dehydroepiandrosterone sulfate to the risk of developing postmenopausal breast cancer. Cancer Res 50: 3859–3862, 1990Google Scholar
  9. 9.
    Helzlsouer KJ, Gordon GB, Alberg AJ, Bush TL, Comstock GW: Relationship of prediagnostic serum levels of dehydroplandrosterone and dehydroeplandrosterone sulfate to the risk of developing premenopausal breast cancer. Cancer Res 52: 1–4, 1992Google Scholar
  10. 10.
    Dorgan JF, Stanczyk F, Longcope C, Stephenson HE, Chang L, Miller R, Franz C, Falk RT, Kahle L: Relationship of serum DHEA, DHEAS and 5-androstene-3β,17β-diol to risk of breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prevention 6: 177–181, 1997Google Scholar
  11. 11.
    Bonney R, Scanlon MJ, Jones DL, Beranek PA, Reed MJ, James VHT: The interrelationship between plasma 5-ene adrenal androgens in normal women. J Steriod Biochem 20: 1353–1355, 1984Google Scholar
  12. 12.
    Huggins C, Jensen EV, Cleveland AS: Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectomized rat. J Exp Med 100: 225–240, 1954Google Scholar
  13. 13.
    Adams J, Garcia M, Rochefort H: Estrogenic effects of physiological concentrations of 5-androstene-3β,17β-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res 41: 4720–4726, 1981Google Scholar
  14. 14.
    Seymour-Munn K, Adams J: Estrogenic effects of 5-androstone-3β,17β-diol and its possible implication in the etiology of breast cancer. Endocrinology 112: 486–491, 1983Google Scholar
  15. 15.
    Poulin R, Labrie F: Stimulation of cell proliferation and estrogenic response by adrenal C195-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res 46: 4933–4937, 1986Google Scholar
  16. 16.
    Spinola PG, Marchetti B, Labrie F: Adrenal steroids stimulate growth and progesterone receptor levels in rat uterus and DMBA-induced mammary tumors. Breast Cancer Res Treat 81: 241–248, 1986Google Scholar
  17. 17.
    Adams JB, Martyn P, Lee F-T, Phillips NS, Smith DL: Metabolism of 17β-estradiol and the adrenal-derived estrogen 5-androstene-3β,17β-diol (Hermaphrodiol) in human mammary cell lines. Ann NY Acad Sci 595: 93–105, 1990Google Scholar
  18. 18.
    Rochefort H, Garcia M: Androgen on the estrogen receptor 1. Binding and in vivo nuclear translocation. Steroids 28: 549–560, 1976Google Scholar
  19. 19.
    Rochefort H, Garcia M: The estrogenic and antiestrogenic activities of androgens in female target tissues. Pharm Ther 23: 193–216, 1984Google Scholar
  20. 20.
    Poulin R, Baker D, Labrie F: Androgens inhibit basal and estrogen-induced cell proliferation in the ZR-75-1 human breast cancer cell line. Breast Cancer Res Treat 12: 213–225, 1988Google Scholar
  21. 21.
    Hackenberg R, Schulz K-D: Androgen receptor mediated growth control of breast cancer and endometrial cancer modulated by antiandrogen-and androgen-like steroids. J Steroid Biochem Mol Biol 56: 113–117, 1996Google Scholar
  22. 22.
    Bocuzzi G, Brignardello E, Di Monaco M, Gatto V, Leonardi L, Pizzini A, Gallo M: 5-En-androstene-3β,17β-diol inhibits the growth of MCF-7 breast cancer cells when oestrogen receptors are blocked by oestradiol. Br J Cancer 70: 1035–1039, 1994Google Scholar
  23. 23.
    Hayward JL, Greenwood FC, Glober G, Stemmerman G, Bulbrook RD, Wang DY, Kamaoka S: Endocrine status in normal British, Japanese and Hawaiian-Japanese women. Eur J Cancer 14: 1221–1228, 1978Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • John B. Adams
    • 1
  1. 1.School of Biochemistry and Molecular GeneticsUniversity of New South WalesSydneyAustralia

Personalised recommendations